SS-31 for Sale — Research-Grade Elamipretide

SS-31 for Sale — Research-Grade Elamipretide

Mitochondrial dysfunction drives aging, neurodegenerative disease, and metabolic collapse. Yet fewer than a dozen compounds have demonstrated the ability to cross the inner mitochondrial membrane and stabilize the organelle's structure from within. SS-31 (elamipretide) is one of them. Unlike antioxidants that scavenge reactive oxygen species after damage occurs, SS-31 binds directly to cardiolipin, the unique phospholipid that anchors cytochrome c and ATP synthase complexes in place, preventing the cascade that leads to mitochondrial fragmentation and cellular energy failure.

We've worked with research institutions studying SS-31 across models of heart failure, Barth syndrome, ischemia-reperfusion injury, and age-related cognitive decline. The compound's mechanism. Cardiolipin stabilization. Is singular, and the results speak to mitochondrial restoration at a structural level that dietary interventions or NAD+ precursors cannot achieve.

What is SS-31 for sale, and why is it used in mitochondrial research?

SS-31 for sale refers to research-grade elamipretide peptide, a mitochondrial-targeted tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that selectively binds to cardiolipin on the inner mitochondrial membrane. It is used in biological research to study mitochondrial bioenergetics, oxidative phosphorylation efficiency, and cellular protection against ischemia, neurodegeneration, and metabolic stress. SS-31 does not function as an antioxidant in the traditional sense. It prevents electron leakage by stabilizing the cristae structure where ATP is generated.

Yes, SS-31 for sale is available through research peptide suppliers. But the critical distinction is purity and sequencing accuracy. Elamipretide contains a non-standard amino acid (dimethyltyrosine, or Dmt) that requires specialized synthesis protocols. Batches with incorrect stereochemistry or substituted residues may appear identical on basic mass spectrometry but lack the mitochondrial-targeting selectivity that defines the compound's mechanism. This article covers how SS-31 works at the molecular level, what differentiates high-purity research-grade elamipretide from generic tetrapeptide analogs, and what researchers should verify before procurement.

How SS-31 Targets Mitochondria and Stabilizes Cardiolipin

SS-31 is a cell-permeable tetrapeptide with an alternating cationic-aromatic sequence (D-Arg-Dmt-Lys-Phe-NH2) that allows it to cross plasma membranes, bypass cytosolic degradation, and accumulate selectively in mitochondria driven by the organelle's negative membrane potential. Once inside, it binds with high affinity to cardiolipin, a dimeric phospholipid found almost exclusively on the inner mitochondrial membrane. Cardiolipin anchors the protein complexes of the electron transport chain. Complexes I, III, IV, and ATP synthase. Maintaining cristae structure and preventing cytochrome c release during apoptotic signaling.

When cardiolipin is oxidized or displaced. As occurs during ischemia, aging, or inherited mitochondrial disorders like Barth syndrome. The cristae flatten, supercomplex assembly fails, and proton leak increases. Reactive oxygen species production spikes not because of increased metabolic demand but because electrons escape the chain at Complexes I and III before reaching cytochrome c oxidase. SS-31 prevents this structural collapse by binding to cardiolipin's negatively charged headgroups, shielding them from peroxidation and stabilizing the curvature required for efficient ATP synthesis. Studies in isolated mitochondria show that SS-31 treatment restores respiratory control ratio (state 3/state 4 respiration) to near-baseline levels even after oxidative insult.

The peptide's D-amino acid at position 1 and the amidated C-terminus confer resistance to peptidases, giving SS-31 a half-life of approximately 3–5 hours in vivo. Long enough for meaningful mitochondrial accumulation without requiring continuous infusion. Research published in Circulation Research demonstrated that SS-31 administered before ischemia-reperfusion reduced infarct size by 40–50% in rodent models, with protection linked directly to preserved cardiolipin content and reduced cytochrome c translocation. The mechanism is not generic antioxidant scavenging. It is structural stabilization of the mitochondrial membrane architecture that generates ATP.

Our experience working with labs studying SS 31 Elamipretide has reinforced that purity matters more than concentration. A 5mg vial of correctly sequenced elamipretide with verified Dmt incorporation outperforms a 10mg vial of generic Arg-Tyr-Lys-Phe analog by orders of magnitude. The latter may bind membranes but lacks the mitochondrial selectivity and cardiolipin affinity that define the compound's therapeutic potential.

Research Applications and Study Models for SS-31

SS-31 has been investigated across preclinical models of cardiovascular disease, neurodegenerative disorders, metabolic dysfunction, skeletal muscle fatigue, and age-related mitochondrial decline. The unifying theme is mitochondrial dysfunction. Conditions where ATP production falls, oxidative stress rises, and cellular bioenergetics fail despite adequate substrate availability. Unlike NAD+ precursors or CoQ10, which support upstream enzymatic activity, SS-31 targets the physical platform where oxidative phosphorylation occurs.

In heart failure models, SS-31 administration improved left ventricular ejection fraction and diastolic relaxation without increasing contractility per se. The benefit arose from improved energetic efficiency, not inotropy. A Phase II clinical trial in heart failure with preserved ejection fraction (HFpEF) published in JACC: Heart Failure showed that SS-31 infusion improved six-minute walk distance and reduced NT-proBNP levels, biomarkers of cardiac stress. The mechanism was traced to improved mitochondrial ATP production in cardiomyocytes, which rely almost entirely on oxidative phosphorylation and are exquisitely sensitive to cardiolipin oxidation.

Neurodegenerative research has used SS-31 in models of Alzheimer's disease, Parkinson's disease, and traumatic brain injury. Neurons have limited glycolytic capacity and high baseline ATP demand. Mitochondrial failure in these cells triggers synaptic dysfunction long before cell death. In APP/PS1 transgenic mice (a model of amyloid pathology), SS-31 treatment reduced amyloid plaque burden, improved spatial memory, and preserved synaptic density in the hippocampus. The effect was attributed to reduced mitochondrial ROS production and prevention of amyloid-beta-induced cardiolipin peroxidation, which otherwise amplifies the neurotoxic cascade.

Barth syndrome. A genetic disorder caused by tafazzin mutations that prevent normal cardiolipin remodeling. Represents one of the most compelling SS-31 research models. Patients with Barth syndrome have abnormal cardiolipin with shortened acyl chains, leading to cardiomyopathy, skeletal muscle weakness, and neutropenia. In tafazzin-deficient yeast and mammalian cell models, SS-31 partially compensated for defective cardiolipin by stabilizing the existing pool, improving respiratory chain supercomplex formation and reducing cytochrome c loss. A Phase II clinical trial in Barth syndrome (NCT01603407) demonstrated improved 6-minute walk distance and reduced fatigue scores, suggesting functional benefit even when the underlying genetic defect remains uncorrected.

Researchers interested in aging biology have used SS-31 in senescence-accelerated mice and naturally aged rodents. Treatment initiated at 18 months (roughly equivalent to human age 60) improved mitochondrial respiration in skeletal muscle, reduced markers of oxidative damage, and extended median lifespan by approximately 8–12% in some cohorts. The mechanism was not telomere extension or senescent cell clearance. It was preservation of mitochondrial function in metabolically active tissues. Similar studies are underway investigating SS-31's effects on sarcopenia, cognitive aging, and healthspan extension.

For labs sourcing SS-31 for sale, study design should account for dose-response relationships and tissue-specific accumulation. Subcutaneous injection in rodents typically uses 3–5 mg/kg daily, while in vitro studies use 1–10 µM depending on cell type and mitochondrial density. Higher concentrations do not necessarily improve outcomes. SS-31's effect plateaus once cardiolipin-binding sites are saturated.

SS-31 for Sale: Purity, Synthesis, and Supplier Verification

SS-31 (elamipretide) synthesis is not trivial. The peptide contains dimethyltyrosine (Dmt), a non-proteinogenic amino acid that must be incorporated during solid-phase peptide synthesis using protected Fmoc-Dmt-OH building blocks. Generic peptide synthesizers often substitute standard tyrosine or phenylalanine, producing a structurally similar but functionally inactive analog. The D-arginine at position 1 and C-terminal amidation add further complexity, requiring epimerization control and post-synthetic modification. High-purity SS-31 for sale should include HPLC chromatograms showing >98% purity and mass spectrometry confirming the exact molecular weight of 640.8 Da for the free base form.

When evaluating suppliers offering SS-31 for sale, request certificates of analysis (CoA) that specify amino acid composition, not just total peptide content. A CoA listing "tetrapeptide, 99% pure" without sequence confirmation is insufficient. The Dmt residue is what confers mitochondrial selectivity, and its absence renders the compound a non-targeted membrane peptide with negligible cardiolipin affinity. Some suppliers offer "SS-31 analog" or "elamipretide-like peptide" at lower cost; these are often Arg-Tyr-Lys-Phe sequences that lack the critical Dmt substitution.

Storage and reconstitution also matter. Lyophilized SS-31 should be stored at −20°C in a desiccated environment. Once reconstituted in sterile water or bacteriostatic water, the solution is stable for 7–10 days at 2–8°C, but extended storage at room temperature accelerates oxidation of the aromatic residues and reduces biological activity. For in vivo studies, prepare fresh aliquots weekly. For in vitro work, single-use aliquots frozen at −80°C maintain activity for several months.

Real Peptides provides SS 31 Elamipretide with full sequence verification, HPLC purity >98%, and confirmed Dmt incorporation through amino acid analysis. Each batch includes third-party mass spectrometry and endotoxin testing to ensure suitability for cellular and animal research. We've seen labs struggle with inactive analogs purchased from lowest-bid suppliers. The cost savings disappear when experiments fail to replicate published results because the peptide lacks the correct residue at position 2.

SS-31 for Sale: Type Comparison

Key Takeaways

• SS-31 (elamipretide) is a mitochondrial-targeted tetrapeptide that stabilizes cardiolipin on the inner mitochondrial membrane, preventing electron transport chain dysfunction and ATP depletion.
• The peptide contains dimethyltyrosine (Dmt) at position 2, a non-standard amino acid critical for mitochondrial selectivity. Generic analogs substituting tyrosine lack this targeting capability.
• Research applications include heart failure, neurodegenerative disease, Barth syndrome, ischemia-reperfusion injury, and age-related mitochondrial decline.
• High-purity SS-31 for sale should include HPLC chromatograms showing >98% purity and mass spectrometry confirming molecular weight of 640.8 Da.
• Lyophilized SS-31 is stable at −20°C; reconstituted solutions remain active for 7–10 days at 2–8°C but degrade at room temperature.
• Subcutaneous dosing in rodent models typically ranges from 3–5 mg/kg daily; in vitro concentrations are 1–10 µM depending on cell type.
• Real Peptides provides sequence-verified elamipretide with confirmed Dmt incorporation, third-party testing, and certificates of analysis for every batch.

What If: SS-31 for Sale Scenarios

What If the SS-31 I Purchased Doesn't Produce Expected Mitochondrial Effects?

Request a certificate of analysis and verify that amino acid composition includes dimethyltyrosine at position 2. Generic tetrapeptide analogs using standard tyrosine or phenylalanine will appear similar on basic mass spectrometry but lack the mitochondrial-targeting selectivity that defines elamipretide's mechanism. If your supplier cannot confirm Dmt incorporation through amino acid analysis (not just total peptide content), the product is likely a non-functional analog. Re-source from a supplier that provides full sequence verification including stereochemistry confirmation for the D-arginine residue.

What If I Need SS-31 for In Vivo Studies but Can Only Find Small-Quantity Vials?

Calculate total study requirements before procurement. A typical rodent dosing regimen at 3 mg/kg for a 25-gram mouse requires 75 µg per injection, or 525 µg per week. A 5mg vial supports approximately 9 weeks of daily dosing for one animal. For multi-animal studies spanning weeks to months, order in bulk and store lyophilized aliquots at −20°C in a desiccated environment. Avoid repeated freeze-thaw cycles of reconstituted solution. Instead, divide the reconstituted peptide into single-use aliquots and freeze at −80°C immediately after preparation. Thaw only what you need for each injection session.

What If SS-31 Produces Unexpected Toxicity in My Cell or Animal Model?

SS-31 has demonstrated a wide therapeutic window in published research, with toxicity rarely observed below 50 mg/kg in rodents. Unexpected adverse effects at standard research doses (1–10 µM in vitro, 3–5 mg/kg in vivo) often reflect contamination, incorrect reconstitution, or endotoxin presence rather than peptide toxicity per se. Verify that your reconstitution medium is sterile and endotoxin-free. Bacteriostatic water containing benzyl alcohol can cause cell toxicity in sensitive primary cultures. Request endotoxin testing results from your supplier; levels should be <1 EU/mg for cell culture and <5 EU/mg for in vivo work. If toxicity persists with verified pure SS-31, consider that your model may have unanticipated sensitivity to mitochondrial membrane stabilization. Some cancer cell lines, for example, rely on mitochondrial dysfunction for survival and show reduced viability when oxidative phosphorylation is restored.

What If I Want to Compare SS-31 to Other Mitochondrial-Targeted Compounds?

SS-31's mechanism. Cardiolipin stabilization. Is distinct from MitoQ (mitochondrial-targeted CoQ10), SkQ1 (mitochondrial-targeted antioxidant), or NAD+ precursors like NMN and NR. MitoQ and SkQ1 scavenge reactive oxygen species after they are generated; SS-31 prevents their formation by stabilizing electron transport chain architecture. NAD+ precursors support enzymatic activity in glycolysis and the TCA cycle but do not address structural mitochondrial damage. For comparative studies, use parallel treatment arms with identical dosing schedules and measure mitochondrial respiration (oxygen consumption rate), ATP production, and cardiolipin oxidation as endpoints. You will find that SS-31 uniquely preserves cristae structure and respiratory control ratio even when ROS scavengers show minimal effect.

The Evidence-Based Truth About SS-31 for Sale

Here's the honest answer: SS-31 for sale is not a generic mitochondrial antioxidant, and treating it as such will lead to failed experiments and wasted resources. The compound's therapeutic mechanism is entirely dependent on the presence of dimethyltyrosine at position 2, which confers mitochondrial-targeting selectivity and cardiolipin-binding affinity that standard amino acid sequences cannot replicate. Suppliers offering "SS-31 analog" or "elamipretide-like peptide" at half the price are almost always selling Arg-Tyr-Lys-Phe. A peptide that will pass basic mass spectrometry but lacks the functional activity that defines elamipretide in peer-reviewed literature.

The evidence for SS-31's efficacy in preclinical models is extensive and mechanistically consistent. Cardiolipin stabilization improves mitochondrial bioenergetics across tissues and disease states. But replicating those results requires the correct molecule, synthesized with stereochemical precision and verified through amino acid composition analysis. A CoA listing "99% purity" without confirming Dmt content is marketing, not science. Researchers who source SS-31 for sale without sequence verification will spend months troubleshooting protocols when the real issue is that the peptide in the vial is not elamipretide.

If your research depends on mitochondrial function. And most aging, cardiovascular, and neurodegenerative studies do. Then SS-31 for sale must meet the same synthesis and purity standards as any other biological tool. Anything less is a variable you cannot control.

SS-31 represents one of the few peptides that can cross the inner mitochondrial membrane and directly stabilize the organelle's structural foundation. When sourced correctly, it is a research tool with singular mechanistic clarity. When sourced from suppliers who substitute residues or skip sequence verification, it is an expensive placebo. Real Peptides provides research-grade elamipretide with confirmed dimethyltyrosine incorporation, third-party purity testing, and sterility verification. The baseline requirements for mitochondrial research that intends to publish. If your study depends on mitochondrial bioenergetics, source SS-31 for sale from suppliers who understand that sequence fidelity is not negotiable.